Stocks and Investing Stocks and Investing
Mon, June 5, 2017
Fri, June 2, 2017
Thu, June 1, 2017

David Amsellem Upgraded (SUPN) to Buy and Increased Target to $44 on, Jun 1st, 2017


Published on 2024-10-25 21:15:33 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Upgraded "Supernus Pharmaceuticals, Inc." (SUPN) to Buy and Increased Target from $30 to $44 on, Jun 1st, 2017.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources